Select Bibliography

Filter by any of these (after searching):

There are 57 items

NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity

Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007

Abstract - Primary - Preliminary - GI - NCCTG-N044J

Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849

Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary - Preliminary - GI - N0849

Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data

Apoe, Ogheneruona , Jung, Sin-Ho , Liu, Heshan , Seisler, Drew K ... - - Am J Hematol Oncol - 2016

Manuscript - Primary - Preliminary - Prevention - CALGB-70806

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010

Abstract - Primary - Preliminary - Leukemia - CALGB-10502

Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance)

Borad, Mitesh J. , Foster, Nathan R. , Martin, Peter R. ... - ESMO GI - Ann. Oncol. - 2016

Abstract - Primary - Preliminary - Experimental - N1153

Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041)

Buzdar, A. U. , Meric-Bernstam, F. , Boughey, J. C. , Leitch, A. M. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary - Preliminary - Breast - ACOSOG-Z1041

Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production

Ding, W. , Shanafelt, T. D. , Lesnick, C. , Sassoon, T. , Secreto, C. ... - ASH - Blood - 2012

Abstract - Primary - Preliminary - Leukemia - N1087

The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea: Preliminary Results from ACOSOG Z4032 Trial

Fernando, H. C. , Landreneau, R. , Mandraker, S. , Hillman, S. ... - AATS - American Association of Thoracic Surgery 90th Annual Meeting - 2010

Abstract - Primary - Preliminary - Respiratory - ACOSOG-Z4032

A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial

Garcia-Aguilar, Julio , Shi, Qian , Thomas, Charles R. , Chan, Emily ... - - Ann. Surg. Oncol. - 2012

Manuscript - Primary - Preliminary - GI - ACOSOG-Z6041

Initial results of CALGB 80803: A randomized phase II trial of pet scan-directed combined modality therapy for esophageal cancer (Alliance)

Goodman, Karyn A. , Niedzwiecki, Donna , Hall, Nathan ... - ASCO GI - J Clin Oncol - 2017

Abstract - Primary - Preliminary - GI - CALGB-80803

A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non small cell lung cancer: CALGB 30407 early evaluation of feasibility and toxicity

Govindan, R. , Bogart, J. A. , Wang, X. , Liu, D. , Kratzke, R. A. ... - - J. Clin. Oncol. - 2008

Abstract - Primary - Preliminary - Respiratory - CALGB-30407

Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB 80405 (Alliance)

Guercio, Brendan J. , Venook, Alan P. , Niedzwiecki, Donna ... - ASCO GI - J Clin Oncol - 2017

Abstract - Secondary - Preliminary - GI - CALGB-80405

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.

Hurwitz, Mark D , Halabi, Susan , Ou, San-San , McGinnis, Lamar S ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2008

Manuscript - Primary - Preliminary - GU - CALGB-99809

Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657

Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - - Cancer Res. - 2009

Abstract - Primary - Preliminary - Breast - CALGB-150007

MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: Preliminary Findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657

Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - RSNA - Radiological Society of North America 94th Scientific Assembly and Annual Meeting - 2008

Abstract - Primary - Preliminary - Breast - CALGB-150007

NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study

Jaeckle, K. A. , Schiff, D. , Anderson, S. K. , Galanis, E. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary - Preliminary - Neuro-Onc - N0572

Phase I/II trial of sorafenib and CCI-779 in patients with recurrent glioblastoma (GBM)

Jaeckle, K. , Anderson, K. , Sarkaria, J. , Decker, P. , Buckner, J. ... - ICTT - - 2008

Abstract - Primary - Preliminary - Neuro-Onc - NCCTG-N0572

A phase I/II trial adding the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel in patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) Alliance A091101

Jelinek, Michael J. , Foster, Nathan R. , Zoroufy, Alex J. ... - ASCO - J Clin Oncol - 2018

Abstract - Primary - Preliminary - Experimental - A091101

Everolimus plus R-CHOP as initial therapy for DLBCL: a phase I/feasibility study (NCCTG N1085 [Alliance])

Johnston, Patrick B. , LaPlant, Betsy R. , Nowakowski, Grzegorz S. ... - ICML - Hematol Oncol - 2015

Abstract - Primary - Preliminary - Lymphoma - N1085

Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B cell lymphoma (DLBCL): NCCTG N1085 (Alliance) phase I and feasibility study

Johnston, Patrick B. , LaPlant, Betsy R. , Nowakowski, Grzegorz S. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary - Preliminary - Lymphoma - N1085

Bortezomib maintenance (BM) vs consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell (MCL): CALGB 50403 (Alliance).

Kaplan, L. D. , Jung, S. H. , Bartlett, N. C. , Johnson, J. , Byrd, J. ... - ASH - Hematol Oncol - 2013

Abstract - Primary - Preliminary - Lymphoma - CALGB-50403

A randomized phase II trial of maintenance vs consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma (MCL): CALGB 50403

Kaplan, L. D. , Jung, S. , Johnson, J. L. , Linker, C. , Byrd, J. C. ... - - J. Clin. Oncol. - 2010

Abstract - Primary - Preliminary - Lymphoma - CALGB-50403

Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E

Katipamula, Rajini , Jatoi, Aminah , Foster, Nathan R. ... - - Clin Med Oncol - 2008

Manuscript - Secondary - Preliminary - GI - N044E

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808

Kolitz, J. E. , Hars, V. , Deangelo, D. J. , Allen, S. L. ... - - Blood - 2007

Abstract - Primary - Preliminary - Leukemia - CALGB-19808 , CALGB-8461 , CALGB-9665

A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E.

Kottschade, L. , Suman, V. , Amatruda, T. , Mcwilliams, R. ... - - J. Clin. Oncol. - 2008

Abstract - Primary - Preliminary - Experimental - N057E

Phase I randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study

Laack, N. N. , Galanis, E. , Leinweber, C. , Buckner, J. C. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Primary - Preliminary - Neuro-Onc - N0877

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101

Lin, T. S. , Donohue, K. A. , Lucas, M. S. , Byrd, J. C. ... - - Blood - 2007

Abstract - Primary - Preliminary - Leukemia - CALGB-10101

Randomized phase II study comparing the met inhibitor cabozantinib to temozolomide (tmz) or dacarbazine (dtic) in ocular melanoma - A091201

Luke, Jason J. , Allred, Jacob B. , Horvath, Laura E. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary - Preliminary - Experimental - A091201

Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II Trial of Gemcitabine, 5-Fluorouracil (5FU), and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma

Mamon, H. J. , Niedzwiecki, D. , Hollis, D. R. , Tan, B. , Smith, J. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2005

Abstract - Primary - Preliminary - GI - CALGB-80003

CALGB 50803 (Alliance): A phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma

Martin, P. , Jung, S.-H. , Johnson, J. , Elstrom, R. , Bartlett, N. L. ... - ICML - Hematol Oncol - 2013

Abstract - Primary - Preliminary - Lymphoma - CALGB-50803

Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): Initial report of patient accrual and adverse events

Mccarthy, P. L. , Linker, C. , Hofmeister, C. C. , Owzar, K. ... - - J. Clin. Oncol. - 2010

Abstract - Primary - Preliminary - Transplant - CALGB-100104

N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC)

Moreno-Aspitia, A. , Rowland, K. M. Jr , Allred, J. B. , Liu, H. ... - AACR - Cancer Res. - 2012

Abstract - Primary - Preliminary - Breast - N0937

A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.

Morrison, V. A. , Johnson, J. L. , Jung, S. , Leonard, J. P. ... - - J. Clin. Oncol. - 2010

Abstract - Primary - Preliminary - Lymphoma - CALGB-50501

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Morrison, V. A. , Jung, S.-H. , Johnson, J. , Lacasce, A. ... - ASH - ASH Annual Meeting Abstracts - 2012

Abstract - Primary - Preliminary - Lymphoma - CALGB-50501

Therapy with bortezomib plus lenalidomide is tolerable in patients (pts) with relapsed/refractory mantle cell lymphoma (MCL): Interim results of CALGB 50501

Morrison, V. A. , Jung, S. , Johnson, J. , Leonard, J. ... - - Ann. Oncol. - 2011

Abstract - Primary - Preliminary - Lymphoma - CALGB-50101

A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501)

Morrison, V. A. , Jung, S. , Leonard, J. ... - - J. Clin. Oncol. - 2011

Abstract - Primary - Preliminary - Lymphoma - CALGB-50501

Adjuvant targeted therapy following standard adjuvant therapy for resected NSCLC: An initial report from ALCHEMIST (Alliance A151216)

Oxnard, Geoffrey R. , Mandrekar, Sumithra , Hillman, Shauna ... - IASLC (WCLC) - J Thorac Oncol - 2018

Abstract - Primary - Preliminary - Respiratory - A151216

The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer

Parsons, J. Kellogg , Pierce, John P. , Mohler, James ... - - BJU Int. - 2018

Manuscript - Secondary-not-in-original - Preliminary - Prevention - CALGB-70807

A phase II study of neoadjuvant therapy with cisplatin, docetaxel, panitumumab plus radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051)

Reed, C. , Decker, P. , Schefter, T. , Meyers, B. , Ferguson, M. ... - - J. Clin. Oncol. - 2012

Abstract - Primary - Preliminary - GI - ACOSOG-Z4051

CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma

Rini, B. I. , Halabi, S. , Rosenberg, J. E. , Stadler, W. M. ... - ASCO GU - Genitourinary Cancers Symposium - 2008

Abstract - Primary - Preliminary - GU - CALGB-90206

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Rini, Brian I. , Halabi, Susan , Rosenberg, Jonathan E. ... - - J Clin Oncol - 2008

Manuscript - Primary - Preliminary - GU - CALGB-90206

The feasibility of breast-conserving surgery for multiple ipsilateral breast cancer: An initial report from ACOSOG Z11102 (Alliance) trial

Rosenkranz, Kari M. , Ballman, Karla , McCall, Linda ... - - Ann. Surg. Oncol. - 2018

Manuscript - Secondary - Preliminary - Breast - Z11102

Interim analysis of CALGB 150607: A pilot project to study the expression of MET and p53 in resected lung adenocarcinoma specimens

Salama, A. K. , Kratzke, R. A. , Richards, W. , Pang, H. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary - Preliminary - Correl Sci NOS - CALGB-150607

An Interim Analysis Of CALGB 150607: Expression And Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, c-CBL, And E-cadherin In Resected Lung Adenocarcinoma Specimens

Salgia, R. , Nallasura, V. , Pang, H. , Rolle, C. , Richards, W. ... - Chicago MSTO - Clin. Cancer Res. - 2012

Abstract - Secondary - Preliminary - Correl Sci NOS - CALGB-150607

Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572

Schiff, D. , Sarkaria, J. , Decker, P. , Buckner, J. , Galanis, E. ... - SNO - Neuro-oncology - 2007

Abstract - Primary - Preliminary - Neuro-Onc - N0572

Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572

Schiff, D. , Sarkaria, J. , Decker, P. , Buckner, J. , Galanis, E. ... - SNO - Neuro-oncology - 2009

Abstract - Primary - Preliminary - Neuro-Onc - N0572

N0321: A Phase I Study of bortezomib, Paclitaxel, Carboplatin (CBDCA) & Radiotherapy (RT) for Locally-Advanced Non-Small Cell Lung Cancer (NSCLC)

Schild, S. , Molina, J. , Dy, G. , Rowland, K., Jr , Sarkaria, J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary - Preliminary - Respiratory - NCCTG-N0321

Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809

Shapiro, C. L. , Halabi, S. , Gibson, G. , Friedlander, R. J. ... - - J. Clin. Oncol. - 2008

Abstract - Primary - Preliminary - Symptom Inter - CALGB-79809

Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy.

Shulman, L. N. , Cirrincione, C. T. , Berry, D. A. , Becker, H. P. ... - SABCS - - 2010

Abstract - Primary - Preliminary - Breast - CALGB-40101

Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer

Sikov, W. , Perou, C. M. , Golshan, M. , Collyar, D. , Berry, D. A. ... - - J. Clin. Oncol. - 2010

Abstract - Primary - Preliminary - Breast - CALGB-40603

Favorable outcomes for adolescents and young adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early results of US Intergroup trial CALGB 10403 (Alliance)

Stock, Wendy , Luger, Selina , Advani, Anjali , Geyer, Susan ... - ASH - Blood - 2014

Abstract - Primary - Preliminary - Leukemia - CALGB-10403

CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML

Stone, R. M. , Dohner, H. , Ehninger, G. , Villeneuve, M. ... - - J. Clin. Oncol. - 2011

Abstract - Secondary - Preliminary - Leukemia - CALGB-10603

Results of US Intergroup Trial of Response-Adapted Chemotherapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

Straus, David J. , Pitcher, Brandelyn N. , Kostakoglu, Lale ... - ASH - Blood - 2015

Abstract - Primary - Preliminary - Lymphoma - CALGB-50604

A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma

Ujjani, C. , Cheson, B. D. ... - ICML - Hematol Oncol - 2013

Abstract - Primary - Preliminary - Lymphoma - A051103

Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)

Uy, Geoffrey L. , Sanford, Ben , Marcucci, Guido , Zhao, Weiqiang ... - ASH - Blood - 2013

Abstract - Primary - Preliminary - Leukemia - CALGB-11001

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results

Venook, A. , Niedzwiecki, D. , Hollis, D. , Sutherland, S. ... - ASCO - J. Clin. Oncol. - 2006

Abstract - Primary - Preliminary - GI - CALGB-80203

Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dara‐rvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for high‐dose therapy (hdt) and autologous stem cell transplantation (asct)

Voorhees, Peter M. , Morris, Michael , Costa, Luciano J. , PhD ... - ASH - Blood - 2017

Abstract - Secondary - Preliminary - Myeloma - AFT-29